Hostname: page-component-76fb5796d-vvkck Total loading time: 0 Render date: 2024-04-25T12:24:27.865Z Has data issue: false hasContentIssue false
  • English
  • Français

Subjective well-being under clozapine measured with the Serbian version of GASS-C: Preliminary results

Published online by Cambridge University Press:  23 March 2020

D. Ignjatovic Ristic ,
C. Dan ,
D. Hinic  and
J. Jovic
D. Ignjatovic Ristic
Affiliation:
Clinical Center Kragujevac, Psychiatric Clinic, Kragujevac, Serbia University of Kragujevac, Faculty of Medical Sciences, Kragujevac, Serbia
C. Dan
Affiliation:
Mental Health Organization North-Holland North, Department of Community psychiatry, Haarlem, The Netherlands
D. Hinic
Affiliation:
University of Kragujevac, Faculty of Science, Kragujevac, Serbia University of Kragujevac, Faculty of Philology and Arts, Kragujevac, Serbia
J. Jovic
Affiliation:
Universiti of Pristina, Kosovska Mitrovica, Department of Preventive Medicine, Faculty of Medicine, Kosovska Mitrovica, Serbia

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Clinical benefits of antipsychotic treatment depend on the efficacy and on the patients’ tolerability and compliance. To reduce patient initiated treatment discontinuation, timely detection of treatment emergent side effects is essential. The Glasgow Antipsychotic Side-effects scale for clozapine (GASS-C) is a recently developed instrument to measure subjectively experienced clozapine side effects.

Objectives

Timely detection of unreported clozapine related side-effects.

Aim

Documenting the prevalence of side-effects in schizophrenia or chronic psychotic disorder with the Serbian version of the GASS-C.

Methods

The sample included 95 in and outpatients with schizophrenia or chronic psychotic disorder. All subjects filled out the Serbian version of the GASS-C and a sociodemographic questionnaire.

Results

The median age was 46.1 years; 53.7% of subjects were male. Clozapine doses ranged from 25 to 423 mg. Drowsiness (78%) was the most commonly reported side-effect. Overall, 16.8% of the patients added other complaints, such as headache, pain, hand or leg numbing or nightmares. According to GASS-C total score categorization [2], only 4.2. % of subjects were rated with severe side-effects, while 14% of themselves rated their symptoms as severe or distressing. More side effects were reported by female patients and by inpatients. Only a weak positive correlation was found between the severity of the side effects and clozapine dosage.

Conclusions

We found the GASS-C to be a useful instrument that elicits both unknown side-effects and patients rating of their severity. Side effects did not clearly relate to the prescribed dose. Future research should include the relation of clozapine plasma levels with side effects assessed with GASS-C.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
e-Poster Viewing: Schizophrenia and other psychotic disorders
Information
European Psychiatry , Volume 41 , Issue S1: Abstract of the 25th European Congress of Psychiatry , April 2017 , pp. s815
Copyright
Copyright © European Psychiatric Association 2017
Submit a response

Comments

No Comments have been published for this article.